Allergy Immunotherapy denied as experimental or investigational by Humana?

Humana's specific coverage criteria for allergy immunotherapy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Allergy Immunotherapy as "Experimental" — and Why You Can Appeal

Allergy immunotherapy — delivered as subcutaneous injections (SCIT) or, in some formulations, as sublingual tablets — has been used clinically for decades and is endorsed by major allergy and immunology specialty organizations as a standard-of-care treatment for allergic rhinitis, allergic asthma, and stinging insect hypersensitivity. An "experimental" or "investigational" denial is most commonly applied to a specific delivery route, allergen extract formulation, or protocol that Humana's medical policy has not yet recognized — such as sublingual drops (SLIT drops, as distinct from FDA-approved sublingual tablets), cluster or rush immunotherapy schedules, or immunotherapy for a less-common allergen category.

These denials are frequently reversed when the prescriber provides guideline-level support and documents the patient's failure to respond to or tolerate alternatives.

## Federal Appeal Rights

• ACA Section 2719 external review is available for most plans; approximately four months from the denial notice is the typical filing window.
• ERISA Section 503 (employer plans) entitles you to a complete written explanation of what evidence standard Humana used and why the specific treatment was classified as investigational.
• Independent external reviewers use peer-reviewed literature and specialty guidelines — not insurer-defined standards alone — to assess whether a treatment is truly experimental.
• Expedited external review is available if delay poses serious health risk (e.g., a patient at risk for anaphylaxis awaiting venom immunotherapy).

## Concrete Appeal Steps and Timeline

1. Obtain the full denial letter; identify whether Humana is denying the entire class of immunotherapy or only a specific delivery method or protocol. 2. File a Level 1 internal appeal with supporting literature and the prescriber's letter. 3. If upheld, file for external review, which independently evaluates whether the treatment meets the generally accepted standard of care per peer-reviewed evidence — a standard immunotherapy readily meets for approved indications.

## Documentation to Gather

• Prescribing allergist's medical necessity and scientific support letter citing the relevant guideline organization (e.g., the American Academy of Allergy, Asthma & Immunology or the Joint Task Force on Practice Parameters) and confirming the treatment is consistent with their published guidance
• Peer-reviewed clinical practice guideline excerpts relevant to the specific allergen and delivery route
• Documentation of prior treatments tried, outcomes, and clinical rationale for the current protocol
• Allergy testing records confirming the diagnosis and specific sensitivities being treated

## Criteria-Mapping Structure

Review Humana's clinical policy for allergy immunotherapy. For each "investigational" criterion:

| Humana Criterion (from policy) | Supporting Documentation | |---|---| | FDA approval or clearance (where applicable) | FDA labeling for the specific product | | Guideline-level endorsement | AAAAI / ACAAI / Joint Task Force citation | | Peer-reviewed evidence of safety and efficacy | Published literature provided by allergist | | Diagnosis-specific indication match | Allergy testing + chart diagnosis |

Emphasize in your appeal that the specific treatment your allergist prescribed is consistent with the applicable specialty society's published practice parameters, and request that Humana apply those same standards — not a narrower internal definition — in their review.